Accumulation of Adipose Tissue in Abdomen. hyperplasia of the abdominal fat tissue (abdominal skin folds higher than 20 mm).
Conditions
Interventions
The abdomen of the participants will be cleaned by using a neutral cleansing soap. They will receive eye protection, using goggles for safety. This will also help with the blindness of the study. PBM
Group B—INFRARED 830±10 nm
Group C—PLACEBO. The treatment will consist of eight sessions that will occur two times a week, totalling 1 month of treatments. The placebo group will use a strap with no light emission, but it will
Device
E02.774
Sponsors
Associação educacional Nove de Julho
Associação educacional Nove de Julho
Eligibility
Age
25 Years to 45 Years
Inclusion criteria
Inclusion criteria: Men and women, 25-45 years old, with BMI between 18.5 kg / m2 to 29.9 kg / m2 will be included; with abdominal fat equal to or greater than 20mm and who agree with the participation in the research by signing the consent form.
Exclusion criteria
Exclusion criteria: The following people will be excluded from this survey: those participants who are undergoing aesthetic treatments to reduce waist circumference; those who have been previously submitted to abdominoplasty or liposuction surgeries; those who are on a diet, in order to reduce their measurements; those people who engage in a physical activity more than two times a week; those who are using or have taken drugs or food supplements in last 90 days, in order to reduce their measurements and their weight, which may affect their lipid metabolism, appetite or nutrients absorption; those who have been submitted previously to oophorectomy; those with signs and/or symptoms of climacteric at the menopause; pregnant or lactating women; those participants who are not regular in attending the sessions; those participants who present metabolic dysfunctions (diabetes and thyroid disorders), cardiovascular problems (hypertension, cardiac insufficiency, arrhythmia, thrombosis, pacemaker use), respiratory issues (asthma, chronic obstructive pulmonary disease), haematological disturbances (anaemia), renal, non-alcoholic fatty liver disease, dermatological or digestive disorders (gastritis, ulcers); those with a history of oncological pathology; those with cognitive deficits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction of abdominal circumference, which will be evaluated through an inelastic anthropometric tape. Measurements will be performed on day zero and after the eighth treatment session and fifteen days after the last session. | — |
Secondary
| Measure | Time frame |
|---|---|
| Observe for changes in lipid profile and markers of liver function after treatment. Measurements will be performed through biochemical blood analysis to be performed on day zero and after the eighth week of treatment and after fifteen days of the last session.;Observe the improvement of quality of life after treatment. The Quality of Life questionnaire will be applied on day zero after the eighth session of treatment and fifteen days after the last session.;Check if there is improvement of the fat percentage through the bioimpedance technique. Measurements will be performed on day zero after the eighth treatment session and fifteen days after the last session.;Observe if there is a reduction in the thickness of the fat layer that will be measured by ultrasonography. Measurements will be performed on day zero and after the eighth treatment session and fifteen days after the last session.;To verify if there is improvement in the self-assessment of the body image, which will be measured through a specific questionnaire. Evaluations will be performed on day zero and after the eighth treatment session and fifteen days after the last session. | — |
Countries
Brazil
Contacts
Public ContactMarcelo Marreira
Universidade Nove de Julho
Outcome results
None listed